EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

MET Dependence Oversteps EGFR Dependence via Balancing Dimerization of the Receptor Tyrosine Kinases in Osimertinib‐Resistant MET ‐Amplified, EGFR ‐Mutated Non‐Small Cell Lung Cancer

Yuri Yagami, Takashi Sato iD, Hiroki Yamamoto, Hiromi Matsuo, Ryosuke Inoue iD, Ryouhei Tsutsumi iD, Mikiko Kakegawa, Yoshiro Nakahara iD, Jiichiro Sasaki iD, Katsuhiko Naoki iD

Thoracic Cancer · 2026-07 · 17 (13)

DOI: 10.1111/1759-7714.70334 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 30.06.2026. Verfasst von Yuri Yagami und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Kitasato University School of Medicine, Sagamihara, Japan. Hauptthemen laut MEDLINE: Aniline Compounds, Proto-Oncogene Proteins c-met, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Naito Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) have substantially improved the clinical outcomes of patients with EGFR ‐mutated non‐small cell lung cancer (NSCLC), most patients ultimately develop acquired resistance. MET amplification is a common resistance mechanism to EGFR‐TKIs; however, its effects on receptor dimerization and the resulting dependence on EGFR or MET signaling have not been fully elucidated.

Methods

We established a classical lung cancer cell line model with acquired resistance to osimertinib, a third‐generation EGFR‐TKI, through exposure to the drug (HCC827OR). Activation profiles of phospho‐receptor tyrosine kinases and genomic alterations were investigated, and drug sensitivity to osimertinib and the MET‐TKI savolitinib was evaluated. EGFR and MET signaling status and dimerization/interaction of EGFR, MET, and ERBB3 were analyzed. In addition, exogenous MET overexpression was introduced into parental HCC827 cells to assess its effects on drug sensitivity and receptor dimerization.

Results

HCC827OR cells exhibited MET amplification and showed sensitivity to savolitinib monotherapy. ERBB3 phosphorylation correlated with the efficacy of the TKIs. Consistently, we found reduced interaction between EGFR and ERBB3 and increased interaction between MET and ERBB3 in HCC827OR cells. MET homodimers and MET‐EGFR interaction increased while EGFR homodimers decreased in those cells. Exogenous MET overexpression in the parental cells partially recapitulated the drug‐resistant phenotype, showing partial sensitivity to savolitinib, increased MET homodimers, and decreased EGFR homodimers.

Conclusions

MET amplification alters the balance of EGFR/MET/ERBB3 dimerization, leading to a shift in signaling dependence from EGFR to MET. These findings provide insight into therapeutic strategies for EGFR ‐mutated NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aniline CompoundsProto-Oncogene Proteins c-metCarcinoma, Non-Small-Cell LungLung NeoplasmsAcrylamidesDrug Resistance, NeoplasmReceptor Protein-Tyrosine KinasesHumansPyrimidinesErbB ReceptorsIndolesMutationProtein Kinase InhibitorsCell Line, Tumor

Stichwörter der Autor:innen

EGFR mutationMET amplificationdimerizationdrug resistancelung cancerosimertinib

Substanzen

PyrimidinesAniline CompoundsProto-Oncogene Proteins c-metErbB ReceptorsIndolesAcrylamidesosimertinibMET protein, humanEGFR protein, humanProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Kitasato University School of Medicine, Sagamihara, Japan.
  • Department of Biochemistry, Kitasato University School of Medicine, Sagamihara, Japan.
  • Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, Sagamihara, Japan.

ORCID-Profile: Takashi Sato, Ryosuke Inoue, Ryouhei Tsutsumi, Yoshiro Nakahara, Jiichiro Sasaki, Katsuhiko Naoki

Förderung

  • Japan Society for the Promotion of Science
  • Naito Foundation

Zitieren

APA

Yagami, Y., Sato, T., Yamamoto, H., Matsuo, H., Inoue, R., Tsutsumi, R., Kakegawa, M., Nakahara, Y., Sasaki, J., & Naoki, K. (2026). MET Dependence Oversteps EGFR Dependence via Balancing Dimerization of the Receptor Tyrosine Kinases in Osimertinib‐Resistant MET ‐Amplified, EGFR ‐Mutated Non‐Small Cell Lung Cancer. Thoracic Cancer, 17(13). https://doi.org/10.1111/1759-7714.70334

Vancouver

Yagami Y, Sato T, Yamamoto H, Matsuo H, Inoue R, Tsutsumi R, et al. MET Dependence Oversteps EGFR Dependence via Balancing Dimerization of the Receptor Tyrosine Kinases in Osimertinib‐Resistant MET ‐Amplified, EGFR ‐Mutated Non‐Small Cell Lung Cancer. Thoracic Cancer. 2026;17(13). doi:10.1111/1759-7714.70334

BibTeX
@article{Yagami2026,
  author = {Yagami, Yuri and Sato, Takashi and Yamamoto, Hiroki and Matsuo, Hiromi and Inoue, Ryosuke and Tsutsumi, Ryouhei and Kakegawa, Mikiko and Nakahara, Yoshiro and Sasaki, Jiichiro and Naoki, Katsuhiko},
  title = {MET Dependence Oversteps EGFR Dependence via Balancing Dimerization of the Receptor Tyrosine Kinases in Osimertinib‐Resistant MET ‐Amplified, EGFR ‐Mutated Non‐Small Cell Lung Cancer},
  journal = {Thoracic Cancer},
  year = {2026},
  volume = {17},
  number = {13},
  doi = {10.1111/1759-7714.70334}
}
Kostenlos starten →